Breast Cancer Research and Treatment

, Volume 85, Issue 2, pp 151–159 | Cite as

Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

  • Michael D. Johnson
  • Hong Zuo
  • Kyung-Hoon Lee
  • Joseph P. Trebley
  • James Michael Rae
  • Ross V. Weatherman
  • Zeruesanay Desta
  • David A. Flockhart
  • Todd C. Skaar
Report

Abstract

The antiestrogen tamoxifen is extensively metabolized in patients to form a series of compounds with altered affinity for estrogen receptors (ERs), the primary target of this drug. Furthermore, these metabolites exhibit a range of partial agonist and antagonist activities for ER mediated effects that do not depend directly on their absolute affinity for ERs. Thus, clinical response to tamoxifen therapy is likely to depend on the aggregate effect of these different metabolites resulting from their abundance in the patient, their affinity for the receptors, and their agonist/antagonist profile. A recent study has shown that plasma concentrations of the tamoxifen metabolite 4-hydroxy-N-desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the cytochrome P450 (CYP) 206 genotype of the patient and that medications commonly prescribed to patients on tamoxifen therapy can also inhibit endoxifen production. In this study we characterized the properties of this metabolite with respect to binding to ERs, ability to inhibit estrogen stimulated breast cancer cell proliferation and the regulation of estrogen responsive genes. We demonstrate that endoxifen has essentially equivalent activity to the potent metabolite 4-hydroxy tamoxifen (4-OH-tam) often described as the active metabolite of this drug. Since plasma levels of endoxifen in patients with functional CYP2D6 frequently exceed the levels of 4-OH-tam, it seems likely that endoxifen is at least as important as 4-OH-tam to the overall activity of this drug and suggests that CYP2D6 status and concomitant administration of drugs that inhibit CYP2D6 activity have the potential to affect response to tamoxifen therapy.

endoxifen estrogen receptor gene expression metabolite proliferation receptor binding tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    American Cancer Society: Cancer Facts and Figures, 2002Google Scholar
  2. 2.
    Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609–1618, 1998Google Scholar
  3. 3.
    Furr BJ, Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127–205, 1984Google Scholar
  4. 4.
    Stearns V, Johnson MD, Rae JM et al.: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95: 1758–1764, 2003Google Scholar
  5. 5.
    Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K: Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: 73–78, 1996Google Scholar
  6. 6.
    Leonessa F, Jacobson M, Boyle B, Lippman J, McGarvey M, Clarke R: Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, andM(r) 170,000 glycoprotein (gp170) binding studies. Cancer Res 54: 441–447, 1994Google Scholar
  7. 7.
    Edwards DP, McGuire WL: 17 alpha-estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. Endocrinology 107: 884–891, 1980Google Scholar
  8. 8.
    Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254, 1976Google Scholar
  9. 9.
    Johnson MD, Westley BR, May FE: Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Br J Cancer 59: 727–738, 1989Google Scholar
  10. 10.
    Jordan VC: Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance. Breast Cancer Res Treat 2: 123–138, 1982Google Scholar
  11. 11.
    Patterson JS, Settatree RS, Adam AK, Kemp JV: Serum concentrations of tamoxifen and major metabolites during longterm Nolvadex therapy, correlated with clinical response. In: Mouridsen HT, Palshoff T (eds) Breast Cancer: Experimental and Clinical Aspects. Pergamon Press, Oxford, UK, 1980, p 89Google Scholar
  12. 12.
    Desta Z, Ward BA, Soukhova N, Flockhart DA: Comprehensive kinetic characterization of tamoxifen primary demethylation and hydroxylation by the human cytochrome P450s. Drug Metab Rev 25(Suppl. 2): 189 (abstract #377), 2003Google Scholar
  13. 13.
    Fisher B, Costantino JP, Wickerham DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998Google Scholar
  14. 14.
    Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D: Hot flushes. Lancet 360: 1851–1861, 2002Google Scholar
  15. 15.
    Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289: 2827–2834, 2003Google Scholar
  16. 16.
    Lien EA, Solheim E, Kvinnsland S, Ueland PM: Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48: 2304–2308, 1988Google Scholar
  17. 17.
    Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49: 2175–2183, 1989Google Scholar
  18. 18.
    Shiau AK, Barstad D, Radek JT et al.: Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9: 359–364, 2002Google Scholar
  19. 19.
    Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR: Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791: 245–253, 2003Google Scholar
  20. 20.
    Marez D, Legrand M, Sabbagh N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193–202, 1997Google Scholar
  21. 21.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA: Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545–558, 1991Google Scholar
  22. 22.
    Rae JM, Cordero KE, Scheys JO, Lippman ME, Flockhart DA, Johnson MD: Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples. Pharmacogenetics 13: 501–507, 2003Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Michael D. Johnson
    • 1
  • Hong Zuo
    • 1
  • Kyung-Hoon Lee
    • 2
  • Joseph P. Trebley
    • 3
  • James Michael Rae
    • 4
  • Ross V. Weatherman
    • 2
  • Zeruesanay Desta
    • 2
  • David A. Flockhart
    • 2
  • Todd C. Skaar
    • 2
  1. 1.Department of Oncology, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashington, DCUSA
  2. 2.Division of Clinical Pharmacology, Department of MedicineIndiana University School of MedicineIndianapolisUSA
  3. 3.Department of Medicinal Chemistry and Molecular PharmacologyPurdue UniversityWest LafayetteUSA
  4. 4.Division of Hematology and Oncology, Department of Internal MedicineUniversity of Michigan Medical CenterAnn ArborUSA

Personalised recommendations